NIH-funded research NIH-funded research

Developing tests to detect and identify infectious bacteria

Official title: Task Area C: NIAID Preclinical Services for AMR Diagnostics Development

Funded at Dynport Vaccine Company, LLC · NIH-10913007 · Data updated 2026-11-12

This study is working on better tests to quickly and accurately find harmful bacteria that can make people sick, helping doctors give the right treatment sooner, especially for infections that are hard to treat.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionDynport Vaccine Company, LLC
NIH-funded
Lab location1 site (Frederick, United States)
Project startJune 20, 2023
Project endJune 19, 2030
Funding year2023
Award (this year)$3,500
NIH project number75N93023D00016-0-759302300001-1
Project IDNIH-10913007 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals experiencing bacterial infections, particularly those with drug-resistant strains.

Less likely to help

Patients with viral infections or those not affected by bacterial pathogens may not receive any benefit from this research.

What this research studies

This research focuses on creating and improving diagnostic tests that can accurately detect and identify various infectious bacteria affecting humans. By utilizing advanced biological assays, the project aims to enhance our understanding of bacterial drug resistance, which is a growing concern in healthcare. Patients may benefit from more effective diagnostic tools that can lead to timely and appropriate treatment options for bacterial infections. The research involves collaboration with various stakeholders to ensure that the developed assays meet clinical needs.

Why it matters

Potential benefit: If successful, this research could lead to more accurate and timely diagnoses of bacterial infections, improving treatment outcomes for patients.

How similar studies have gone: Previous research has shown success in developing diagnostic assays for infectious agents, indicating that this approach has potential for impactful results.

Where this research is happening

  • Dynport Vaccine Company, LLC
    Frederick, United States
    Active

Researchers

  • Principal investigator: Kallarkal, Abraham — Dynport Vaccine Company, LLC
  • Study coordinator: Kallarkal, Abraham

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.